Comparative Pharmacology
Head-to-head clinical analysis: ANTITUSSIVE versus PROVAL 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTITUSSIVE versus PROVAL 3.
ANTITUSSIVE vs PROVAL #3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antitussives suppress cough by acting on the cough center in the medulla oblongata (central antitussives) or by anesthetizing stretch receptors in the respiratory tract (peripheral antitussives).
Proval #3 is a combination of acetaminophen (paracetamol), butalbital, and caffeine. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in the CNS, raising the pain threshold. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation and anxiolysis. Caffeine is a CNS stimulant that potentiates analgesic effects via adenosine receptor antagonism.
For dextromethorphan: 10-20 mg orally every 4-6 hours, maximum 120 mg/day. For codeine: 10-20 mg orally every 4-6 hours, maximum 120 mg/day.
1-2 tablets orally every 4-6 hours as needed for pain; not to exceed 8 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 3-6 hours in adults; prolonged in renal impairment (up to 12-18 hours).
4–6 hours in adults with normal hepatic function; prolonged in hepatic impairment (8–12 hours).
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates) accounts for approximately 60-80% of elimination, with biliary/fecal excretion contributing 15-25%.
Primarily hepatic metabolism (CYP450) with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for ~15% as metabolites.
Category C
Category C
Antitussive
Antitussive